Natixis Advisors LLC Boosts Stock Holdings in Medpace Holdings, Inc. $MEDP

Natixis Advisors LLC increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.9% in the 4th quarter, HoldingsChannel reports. The firm owned 163,360 shares of the company’s stock after purchasing an additional 13,412 shares during the period. Natixis Advisors LLC’s holdings in Medpace were worth $91,751,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. BOKF NA raised its holdings in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after purchasing an additional 20 shares in the last quarter. Valeo Financial Advisors LLC raised its holdings in Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares in the last quarter. HighPoint Advisor Group LLC raised its holdings in Medpace by 2.8% during the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares in the last quarter. Kaufman Rossin Wealth LLC grew its position in Medpace by 3.4% during the fourth quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock worth $447,000 after buying an additional 26 shares during the period. Finally, Berkeley Inc grew its position in Medpace by 1.0% during the fourth quarter. Berkeley Inc now owns 2,694 shares of the company’s stock worth $1,513,000 after buying an additional 27 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Glancy Prongay Wolke & Rotter, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, the Schall Law Firm, and others, are urging investors to act on a securities class action against Medpace tied to purchases made between April 22, 2025 and February 9, 2026. The repeated deadline reminders keep legal overhang and potential litigation costs in focus. Article: Pomerantz investor alert on Medpace class action
• Negative Sentiment: The legal campaign may raise concerns about possible damages, reputational pressure, and management distraction, which can act as a headwind for the shares until the lawsuit situation becomes clearer. Article: Rosen deadline reminder for Medpace investors
• Neutral Sentiment: Medpace General Counsel Stephen P. Ewald disclosed the sale of 16,349 shares at $450 each. Insider selling can attract investor attention, but one transaction does not necessarily indicate a broader operational issue. Article: SEC Form 4 filing for Stephen P. Ewald

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on MEDP shares. BMO Capital Markets lowered their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research report on Friday, February 13th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and lowered their target price for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Barclays lowered their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Finally, Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $467.08.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is owned by corporate insiders.

Medpace Price Performance

MEDP stock opened at $445.59 on Wednesday. The company’s 50 day simple moving average is $457.28 and its 200-day simple moving average is $512.30. The firm has a market capitalization of $12.73 billion, a PE ratio of 28.01, a P/E/G ratio of 2.29 and a beta of 1.18. Medpace Holdings, Inc. has a 12 month low of $293.20 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.